The'FIDO' Strategy Behind Onyx Deal
The 'FIDO' strategy behind Onyx deal
Onyx Pharmaceuticals' five-year R&D agreement with Miles Inc. illustrates the value research boutiques can garner from their skills, according to Hollings Renton, president and CEO.
The deal, worth up to $75 million,